South Korea's Graphy has signed a KRW 2 billion supply agreement with MegaGen Implant for digitally manufactured dental restorations. The package includes Tera Harz E-Namel resin, 3D printers, nitrogen curing units and resin-removal equipment. It is therefore an integrated manufacturing workflow rather than a simple material sale.

Intended uses for E-Namel

Graphy positions the material for direct crowns, bridges, inlays and onlays. Its disclosed composition is a polymer matrix with 53% inorganic ceramic filler. The filled resin seeks aesthetics, wear resistance and machinability suitable for durable restorations, but performance also depends on printing and post-curing.

Korean regulatory status requires precise wording. The company says it obtained Class II medical-device manufacturing authorisation for 'resin for dental crowns' on 7 September and launched the product on 15 September. An FDA 510(k) submission has been filed, but the source reports no clearance; it must not be described as approved in the United States.

The workflow is part of the product

For dental resin, printer, layer height, exposure, orientation, washing, drying, nitrogen post-cure and polishing jointly determine the final material. The equipment in the contract suggests that the parties intend to deliver a controlled chain. Each clinic or laboratory must still record lot, profile, maintenance, post-processing and release.

Nitrogen curing can reduce oxygen inhibition at the surface, but does not make every geometry compliant. Intaglio fit, wall thickness, contacts, occlusion and residual monomer must remain within a validated process window.

The business relationship behind the contract

The arrangement also sits within a corporate linkage: Graphy acquired 26.14% of imaging company Ray, where MegaGen is the second-largest shareholder. The parties are also negotiating an annual CBCT supply contract. This could form an ecosystem from imaging through design to production, but the KRW 2 billion headline does not disclose timing of deliveries, revenue recognition or profit.

Limits of the clinical claims

MegaGen's chair cited experience with roughly 50 cases and favourable characteristics versus zirconia. This is a corporate expert account, not a publicly described controlled clinical trial. Durability, wear, staining, repair and biological safety require longer-term independent evidence.

Verified fact, company claim and conclusion

Verified items are the announced contract, value, supplied package, reported date of Korean manufacturing authorisation and pending FDA submission. Clinical advantages and the zirconia comparison are company claims. LAYERTIMES concludes that the news is important for packaging a complete digital chain commercially, while broader adoption still depends on regulatory decisions, public mechanical data and independent clinical follow-up.